Premium
Unusual immunophenotypes in acute leukaemias: incidence and clinical correlations
Author(s) -
Bradstock K. F.,
Kirk J.,
Grimsley P. G.,
Kabral A.,
Hughes W. G.
Publication year - 1989
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1989.tb04315.x
Subject(s) - immunophenotyping , medicine , incidence (geometry) , myeloid , antigen , immunology , acute lymphocytic leukemia , antibody , disease , chemotherapy , leukemia , gastroenterology , lymphoblastic leukemia , physics , optics
Summary The incidence and clinical implications of unusual patterns of expression of leucocyte differentiation antigens in acute leukaemia were assessed on 568 newly diagnosed paediatric and adult cases undergoing immunophenotyping with a panel of monoclonal antibodies at a single centre. Among patients with the precursor B (common) form of acute lymphoblastic leukaemia (ALL), the major variant seen was the group of 15 cases with expression of myeloid surface antigens. 4·5% of ALL cases tested with antibody to CD‐11b were positive, 5·1% were CD‐13 + , and 10·8% CD‐33 + . All 15 patients achieved a complete remission with chemotherapy, with six of eight children and four of seven adults remaining disease free. A smaller proportion (1–5%) of precursor B ALL patients showed expression of the T lineage marker, CD‐7. The only significant variant seen in the precursor T‐ALL group was expression of HLA‐DR antigen, which was found in five of 3 5 cases; although all responded to treatment, only one remains a disease‐free survivor. Among patients with acute myeloid leukaemia (AML), expression of the lymphoid markers terminal transferase (TdT) and CD‐7 were commonly seen (22·2% and 28·4% respectively of cases tested). Other lymphoid markers detected on AML cases were CD2 (11·1%), CD‐10 (1%) and CD‐19 (4·4%). These results confirm that examples of lineage infidelity are regularly seen in large series of patients with acute leukaemia. Prospective studies using uniform treatment protocols are required to establish whether these patients have significantly different disease outcomes.